PCM
PLX icon

Penserra Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Penserra Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,680
Closed -$5.38K – 1006
2016
Q1 		$5.38K Buy
1,680
+534
+47% +$4.58K 0.52% 42
2015
Q4 		$12K Buy
+1,146
New +$11.7K ﹤0.01% 493

Other funds holding PLX

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Penserra Capital Management's PLX Position: Q2 2016 in Review

Penserra Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2016, closing a stake of 1,680 shares — an estimated $5.38K sold.

Penserra Capital Management first reported a position in PLX in Q4 2015 and held it in 2 quarters. The position peaked at $12K in Q4 2015. 28 funds tracked by Wall St. Rank hold PLX as of Q2 2016.

  • Penserra Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2016 after selling out during the quarter.
  • Penserra Capital Management sold 1,680 Protalix BioTherapeutics shares in Q2 2016, an estimated $5.38K.
  • Penserra Capital Management first reported a position in Protalix BioTherapeutics in Q4 2015 and held it in 2 quarters.
  • Penserra Capital Management's Protalix BioTherapeutics position peaked at $12K in Q4 2015.
  • 28 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2016.

Based on Penserra Capital Management's 13F filing for Q2 2016, filed 9 Aug 2016.